Professor Robert Hills
Contact information
Research groups
- The Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
- A comparison of individual patient data (IPD) over meta-analyses of published data, implications for clinical trial design and the utility of endpoints for early breast cancer trials. CRUK STUDENTSHIP AVAILABLE
- Assessing benefits and harms in early breast cancer: predictive and prognostic factors in early breast cancer and long-term side-effects of therapy. CRUK STUDENTSHIP AVAILABLE
Robert Hills
Professor of Medical Statistics
Robert Hills joined the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU) in 1993 as a programmer on the QUASAR trial in colorectal cancer. Following a brief period working in low temperature physics at the University of Nottingham, he moved to the University of Birmingham Clinical Trials Unit (BCTU) in 1997.There, he worked on clinical trials in Acute Myeloid Leukaemia, Alzheimer’s Disease, women’s health and many others as well as large scale individual patient data meta-analyses of treatment for colorectal cancer.
In 2006, he moved to Cardiff University as statistical lead for the NCRI/MRC trials in Acute Myeloid Leukaemia. During his 12 years in Cardiff he was head of the Haematology Clinical Trials Unit, and latterly led on clinical cancer research methodology and haematological malignancies.
The novel designs used in these trials allow the clinical value of disease monitoring to be evaluated, as well as numerous targeted therapies in designs that allow for an early change from an unpromising new therapy to one with greater potential. Additionally, he continued his work on the integration of laboratory and clinical data, and on individual patient data meta-analyses, where he demonstrated a survival benefit for gentuzumab ozogamicin in AML.
In 2018, he moved back to the University of Oxford where he is part of the Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
He studied mathematics at the University of Oxford, where his DPhil was on exploration of symmetries with applications to superconductivity.
Recent publications
-
Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial.
Russell NH. et al, (2025), J Clin Oncol, 43, 694 - 704
-
Review of the target trial methodological approach on treatment effect estimates in kidney failure: protocol for a systematic assessment.
Pinter J. et al, (2024), Syst Rev, 13
-
Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients.
Halik A. et al, (2024), J Hematol Oncol, 17
-
Evaluation of CD3 and CD8 T-Cell Immunohistochemistry for Prognostication and Prediction of Benefit From Adjuvant Chemotherapy in Early-Stage Colorectal Cancer Within the QUASAR Trial.
Williams CJM. et al, (2024), J Clin Oncol
-
Benefits and risks of anthracyclines in early-stage breast cancer - Authors' reply.
Braybrooke J. et al, (2024), Lancet, 403